-
- 2025-06-04
Updated Data of Luvometinib (FCN-159) Treating Pediatric Patients with Neurofibromatosis Type 1 Announced at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
-
The updated data of efficacy and safety of Luvometinib (FCN-159), a self-developed innovative drug by Fosun Pharma, in pediatric participants with neurofibromatosis type 1 from a phase 2 study was presented in the American Society of Clinical Oncology (ASCO) Annual Meeting on May 22, 2025
-
-
- 2021-11-17
Active Cooperation with Outstanding Scientific Talents from All Over the World — Fosun Pharma Welcomes Prof. Zhihong Jiang to Join its Academician Expert Workstation
-
Recently, experts have settled in the Academician Workstation of Fosun Pharma, including Professor Jiang Zhihong, Vice President of Macau University of Science and Technology. Professor Jiang Zhihong is an internationally renowned natural pharmaceutical chemist, studying fields such as natural pharmaceutical chemistry, metabolomics, quality standard of traditional Chinese medicine (TCM) and bioorganic chemistry.
-
-
- 2021-11-07
Innovation for Health — The Fourth Hongqiao International Health Technology Innovation Forum Held in Shanghai
-
On November 6, 2021, as a parallel supporting event of the 4th China International Import Expo (CIIE), the 4th Hongqiao International Health Technology Innovation Forum with the theme of "Innovation for Good Health" was successfully held. This forum was sponsored by the International Health Exchange and Cooperation Center NHC PRC (IHECC) and China Pharmaceutical Innovation and Research Development Association, undertaken by Shanghai Biopharmaceutics Industry Association, Fosun International Limited and Fosun Pharma, and supported by Shanghai Municipal Health Commission, Shanghai Municipal Commission of Economy and Informatization, Science and Technology Commission of Shanghai Municipality and Shanghai Municipal Medical Products Administration.
-
-
- 2021-10-28
Nature Dialogue with Dr. Aimin Hui: How to Lead R&D of Innovator Drugs?
-
Chinese pharmaceutical companies are turning their attention to innovation, shifting rapidly from mastery of follow-on drugs to researching first-in-class and best-in-class drugs. Aiming to be a healthcare group with a global presence, Fosun Pharma, established in Shanghai in 1994, has built its core business around innovative drug R&D and manufacturing.
-
-
- 2021-09-28
2021 CSCO | Henlius Publishes Newest Phase II Clinical Data of Novel Anti-PD-1 mAb Serplulimab for Treatment of Advanced Cervical Cancer
-
In this meeting, Henlius releases phase 2 study results of serplulimab (HLX10, novel anti-PD-1 antibody), in patients with advanced cervical cancer in an oral presentation.
-
-
- 2021-09-28
2021 CSCO | Henlius Publishes Phase III Clinical Data of Bevacizumab Biosimilar HLX04 for Treatment of Metastatic Colorectal Cancer
-
In this meeting, Henlius releases phase 3 study results of HLX04 (bevacizumab biosimilar), in patients with metastatic colorectal cancer in an oral presentation.
-
-
- 2021-09-28
2021 CSCO | Henlius Publishes Phase II Clinical Data of Novel Anti-PD-1 mAb Serplulimab for 'Pan-cancer' Treatment of MSI-H Solid Tumors
-
In this meeting, Henlius releases phase 2 study results of serplulimab (HLX10, novel anti-PD-1 antibody), in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) solid tumours in an oral presentation.
-
-
- 2021-09-06
Dr. Aimin Hui, President of Fosun Pharma Global R&D, Granted the 4th "China Translational Medicine Award - International Collaboration"
-
On September 5, the awarding ceremony of the 4th "China Translational Medicine Award" was held in Beijing. Dr. Aimin Hui, Fosun Pharma's executive president, president of global R&D, and chief medical officer, was granted the 4th "China Translational Medicine Award - International Collaboration".
-